SCHEMBL10003208

SCHEMBL10003208

CCOC(=O)c1c(OCC(F)(F)F)c2cc(N=C(c3ccccc3)c3ccccc3)c(CC)nc2n1C

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.35
▸ KDM4E B2RXH2 5/20 0.35
▸ HPGD P15428 4/20 0.35
▸ MAPT P10636 3/20 0.35
▸ ELANE P08246 3/20 0.35
▸ HSD17B10 Q99714 2/20 0.35
▸ TSHR P16473 2/20 0.35
▸ CASP1 P29466 1/20 0.35
▸ CASP7 P55210 1/20 0.35
▸ SMN1; SMN2 Q16637 3/20 0.34
▸ CYP1A2 P05177 3/20 0.34
▸ CYP2C9 P11712 3/20 0.34
▸ CYP2C19 P33261 3/20 0.34
▸ MAPK1 P28482 2/20 0.34
▸ ALOX15 P16050 2/20 0.34
▸ HCRTR1 O43613 1/20 0.34
▸ TP53 P04637 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ LMNA P02545 1/20 0.33
▸ CDC25B P30305 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10003033 0.85 MAPT (0.36) ALDH1A1KDM4EMAPTELANESMN1; SMN2
SCHEMBL10003156 0.84 KDM4E (0.41) ALDH1A1KDM4EHPGDMAPTHSD17B10
SCHEMBL10003975 0.83 RAB9A (0.42) ALDH1A1KDM4EHPGDMAPTHSD17B10
SCHEMBL10003336 0.82 SMN1; SMN2 (0.41) ALDH1A1KDM4EHPGDMAPTELANE
SCHEMBL10004365 0.82 MAPT (0.41) ALDH1A1KDM4EHPGDMAPTHSD17B10
SCHEMBL10003159 0.81 CDC25B (0.44) MAPTSMN1; SMN2TP53CDC25BNPSR1
Hydrochloric Acid SCHEMBL10003805 0.81 MAPT (0.41) ALDH1A1KDM4EHPGDMAPTHSD17B10
SCHEMBL10004215 0.80 HPGD (0.42) ALDH1A1KDM4EHPGDMAPTHSD17B10
SCHEMBL12003634 0.80 KDM4E (0.38) ALDH1A1KDM4EHPGDMAPTHSD17B10
SCHEMBL10004038 0.80 NPSR1 (0.41) ALDH1A1KDM4EHPGDMAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471789-B9 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-03-25 — — EP disclosed
EP-2471789-B1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2014-09-17 — — EP disclosed
US-8486965-B2 Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-16 — — US disclosed
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-30 — — US disclosed
EP-2471789-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF SMO, GLI1, SHH ALDH1A1 321/4885KDM4E 405/4885HPGD 539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback